Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

被引:29
作者
Alba, M. [1 ]
Ahren, B. [2 ]
Inzucchi, S. E. [3 ]
Guan, Y. [1 ]
Mallick, M. [1 ]
Xu, L. [1 ]
O'Neill, E. A. [1 ]
Williams-Herman, D. E. [1 ]
Kaufman, K. D. [1 ]
Goldstein, B. J. [1 ]
机构
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Lund Univ, Dept Clin Sci, Lund, Sweden
[3] Yale Univ, Sch Med, Dept Endocrinol, New Haven, CT USA
关键词
dipeptidyl peptidase-4 inhibitors; DPP-4; incretins; MK-0431; PPAR agonist; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; INITIAL COMBINATION THERAPY; GLYCEMIC CONTROL; INSULIN SENSITIVITY; BLADDER-CANCER; TOLERANCE TEST; DOUBLE-BLIND; TYPE-2; MONOTHERAPY; PLACEBO;
D O I
10.1111/dom.12145
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The effects of sitagliptin and pioglitazone, alone and in combination, on alpha- and beta-cell function were assessed in patients with type 2 diabetes. Methods Following a 6-week diet/exercise period, 211 patients with HbA1c of 6.5-9.0% and fasting plasma glucose of 7.2-14.4mmol/l were randomized (1:1:1:1) to sitagliptin, pioglitazone, sitagliptin+pioglitazone or placebo. At baseline and after 12 weeks, patients were given a mixed meal followed by frequent blood sampling for measurements of glucose, insulin, C-peptide and glucagon. Results After 12weeks, 5-h glucose total area under the curve (AUC) decreased in all active treatments versus placebo; reduction with sitagliptin + pioglitazone was greater versus either monotherapy. The 5-h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. The 3-h glucagon AUC decreased with sitagliptin versus placebo and decreased with sitagliptin + pioglitazone versus pioglitazone or placebo. phi(s), a measure of dynamic beta-cell responsiveness to above-basal glucose concentrations, increased with either monotherapy versus placebo and increased with sitagliptin + pioglitazone versus either monotherapy. The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. The disposition index, a measure of the relationship between beta-cell function and insulin sensitivity, improved with all active treatments versus placebo. Conclusions Sitagliptin and pioglitazone enhanced beta-cell function (increasing postmeal phi(s)), and sitagliptin improved alpha-cell function (decreasing postmeal glucagon) after 12weeks in patients with type 2 diabetes. Through these complementary mechanisms of action, the combination of sitagliptin and pioglitazone reduced postmeal glucose more than either treatment alone.
引用
收藏
页码:1101 / 1110
页数:10
相关论文
共 48 条
[1]   Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin [J].
Ahren, Bo .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2010, 3 :31-41
[2]  
Alba M, 2009, IDF ABSTR BOOK, p[P, 584]
[3]  
[Anonymous], 2008, CAN J DIABETES, V32, pS53
[4]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[5]   Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].
Aschner, Pablo ;
Kipnes, Mark S. ;
Lunceford, Jared K. ;
Sanchez, Matilde ;
Mickel, Carolyn ;
Williams-Herman, Debora E. .
DIABETES CARE, 2006, 29 (12) :2632-2637
[6]   Effects of type 2 diabetes on the regulation of hepatic glucose metabolism [J].
Basu, A ;
Shah, P ;
Nielsen, M ;
Basu, R ;
Rizza, RA .
JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (06) :366-374
[7]   The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes [J].
Bergman, RN ;
Finegood, DT ;
Kahn, SE .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :35-45
[8]   Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes [J].
Brazg, R. ;
Xu, L. ;
Dalla Man, C. ;
Cobelli, C. ;
Thomas, K. ;
Stein, P. P. .
DIABETES OBESITY & METABOLISM, 2007, 9 (02) :186-193
[9]   Oral glucose tolerance test minimal model indexes of β-cell function and insulin sensitivity [J].
Breda, E ;
Cavaghan, MK ;
Toffolo, G ;
Polonsky, KS ;
Cobelli, C .
DIABETES, 2001, 50 (01) :150-158
[10]   Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests [J].
Cobelli, Claudio ;
Toffolo, Gianna Maria ;
Dalla Man, Chiara ;
Campioni, Marco ;
Denti, Paolo ;
Caumo, Andrea ;
Butler, Peter ;
Rizza, Robert .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 293 (01) :E1-E15